Show simple item record

dc.contributor.authorPanahi, Y
dc.contributor.authorJadidi-Niaragh, F
dc.contributor.authorJamalkandi, SA
dc.contributor.authorGhanei, M
dc.contributor.authorPedone, C
dc.contributor.authorNikravanfard, N
dc.contributor.authorNikravesh, F
dc.contributor.authorSahebkar, A
dc.date.accessioned2018-08-26T07:41:10Z
dc.date.available2018-08-26T07:41:10Z
dc.date.issued2016
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/47435
dc.description.abstractBackground: Sulfur mustard (SM)-induced airway injuries and chronic obstructive pulmonary disease (COPD) are characterized by chronic inflammation of the respiratory tract and share some similarities regarding the cellular and molecular mechanisms orchestrating airway destruction. Since available data regarding the immunobiology of COPD is much more known compared with SM-mediated injuries, and considering the similarities in the immunopathogenesis of these diseases, comparison of the immunopathogenesis of COPD and SM-induced respiratory complications can help designing new therapeutic approaches for treatment of SM-induced injuries. Methods: A multi-database search was performed to identify articles dealing with the role of immune system function in the pathogenesis of COPD and mustard mustard-induced respiratory complications. Results: This review outlines the role of different components of the immune system in the pathogenesis of COPD and mustard-induced respiratory complications, and suggests therapeutic implication for improving the management of the latter condition as the most common chronic complication of sulfur mustard exposure. Conclusion: Although COPD and mustard lung are overlapping phenotypes and have shared pathophysiologic features, there are certain differences between these two diseases that necessitate further scrutiny. Combination therapies to counterbalance inflammation, oxidative stress and immune imbalance hold promise for the management of SM-induced respiratory complications but the success of such combined treatments need to be confirmed in proof-of-concept trials.
dc.language.isoEnglish
dc.relation.ispartofCURRENT PHARMACEUTICAL DESIGN
dc.subjectImmunology
dc.subjectchronic obstructive pulmonary disease
dc.subjectsulfur mustard
dc.subjectlung
dc.subjectairway injury
dc.subjecttreatment
dc.titleImmunology of Chronic Obstructive Pulmonary Disease and Sulfur Mustard Induced Airway Injuries: Implications for Immunotherapeutic Interventions
dc.typeArticle
dc.citation.volume22
dc.citation.issue20
dc.citation.spage2975
dc.citation.epage2996
dc.citation.indexWeb of science
dc.identifier.DOIhttps://doi.org/10.2174/1381612822666160307150818


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record